Close

Please fill all fields and submit the form.

Name:
Email:

Phone:

Notes:



Close

Please fill out all fields in the form. Please be as detailed as possible. We will respond with pricing and availability within 1-2 business days.

Name:
Company/Institution:

Phone:
Email:

Disease:

Organ/Tissue type:

Format:

Number of patients/donors required for the study:

Clinical Specifications:

Applications/Research topic:

KRAS 19 Mutations Detection Kit

Detection of 19 mutations in KRAS codons 12, 13, 59, 61, 117 and 146

KRAS 19 Mutations Detection Kit Description

KRAS protein is a small GTPase and one of the key molecules in the downstream signaling pathway of epidermal growth factor receptor (EGFR). KRAS protein transduces signals from membrane-bound receptors via multiple downstream effector pathways and thereby affects fundamental cellular processes, including proliferation, apoptosis, and differentiation.

Intended use: RUO

KRAS mutations are particularly common in colon cancer, lung cancer, and pancreatic cancer. In total, activating mutations in the KRAS genes occur in 15~30% of lung cancer and 20~50% of colorectal cancer, mainly in exons 2, 3 or 4. The KRAS gene mutation status of colorectal cancer patients is relevant to drug resistance of targeted medicines such as tyrosine kinase inhibitors. Patients with wild-type KRAS gene are much more likely to benefit from the Erbitux (Cetuximab) or Vectibix (Panitumumab), compared to patients with a mutant KRAS gene. The European Drug Administration Organization and US FDA recommend the employment of a KRAS gene mutation test prior to the usage of targeted medicine Erbitux and and Vectibix in the treatment of colorectal cancer.